Fig 1. Chemical inhibition of ABCC6 but not ABCB1 increases the efficacy of nilotinib in patient MNCs.

p-CRKL determined IC50^NIL was determined via incubating patient MNCs with increasing concentrations of nilotinib in the absence and presence of (A) three ABCB1 inhibitors: PSC-833, verapamil and pantoprazole and (B) three ABCC6 inhibitors: pantoprazole, indomethacin, probenecid. CRKL western blotting was performed to determine the concentration of nilotinib required for 50% Bcr-Abl kinase inhibition (IC50^NIL). Representative western blots are shown in S1 Fig. The box plots depict the median, the upper 25th and the lower 75th percentiles while the whiskers encompass the 10th and 90th percentiles. Statistical analyses were performed using Student’s t-test with statistically significant p-values denoted by asterisks (*** p<0.001). NIL = nilotinib.